Single-dose GnRH agonist administration in the luteal phase of GnRH antagonist cycles: a prospective randomized study

By Isik AZ   Caglar GS   Sozen E   Akarsu C   Tuncay G   Ozbıcer T   Vicdan K  

Reproductive BioMedicine Online, Vol. 19, Iss. 4, 2009-10 ,pp. : 472-477

Reproductive Healthcare Ltd

Access to resources Recommend Favorite

Comparable effectiveness using flexible single-dose GnRH antagonist (cetrorelix) and single-dose long GnRH agonist (goserelin) protocol for IVF cycles - a prospective, randomized study

By Vlaisavljevic Veljko   Reljic Milan   Lovrec Vida Gavric   Kovacic Borut  

Reproductive BioMedicine Online, Vol. 7, Iss. 3, 2003-10 ,pp. : 301-308

Reproductive Healthcare Ltd

Access to resources Recommend Favorite

Ovarian responses to recombinant FSH or HMG in normogonadotrophic women following pituitary desensitization by a depot GnRH agonist for assisted reproduction

By Balasch Juan   Peñarrubia Joana   Fábregues Francisco   Vidal Ester   Casamitjana Roser   Manau Dolors   Carmona Francisco   Creus Montserrat   Vanrell Juan A  

Reproductive BioMedicine Online, Vol. 7, Iss. 1, 2003-07 ,pp. : 35-42

Reproductive Healthcare Ltd

Access to resources Recommend Favorite

GnRH agonist versus GnRH antagonist in poor ovarian responders: a meta-analysis

By Franco JG   Baruffi RLR   Mauri AL   Petersen CG   Felipe V   Cornicelli J   Cavagna M   Oliveira JBA  

Reproductive BioMedicine Online, Vol. 13, Iss. 5, 2006-11 ,pp. : 618-627

Reproductive Healthcare Ltd

Access to resources Recommend Favorite

Safety and efficacy of a 3 mg dose of the GnRH antagonist cetrorelix in preventing premature LH surges: report of two large multicentre, multinational, phase IIIb clinical experiences

By Olivennes F   Diedrich K   Frydman R   Felberbaum RE   Howles CM  

Reproductive BioMedicine Online, Vol. 6, Iss. 4, 2003-06 ,pp. : 432-438

Reproductive Healthcare Ltd

Access to resources Recommend Favorite